DAWn PLASMA TRIAL
Sponsored by the Belgian Health Care Knowledge Center (KCE)
Published in European Respiratory Journal: Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
The Donated Antibodies Working agaiNst SARS-CoV-2 plasma (DAWN-plasma) study is a large Belgian clinical study, that will evaluate whether early plasma transfusions from patients who recovered from COVID-19, are effective to mitigate the course of the disease in new COVID-19 patients.
Convalescent plasma is plasma from patients who recovered from an infection. After a COVID-19 infection, antibodies against the virus may be found in the plasma, the watery part of the blood. Starting in April, the Belgian Red Cross has called and screened potential donors. Following a strict procedure, including standardized testing to ensure the plasma contains sufficient antibodies against the coronavirus, as well as safety tests, COVID-19-convalescent plasma has been prepared, and made available to be administered to new patients.
We will investigate whether the administration of COVID-19-convalescent plasma can reduce the proportion of patients that need mechanical ventilation. Being saved from mechanical ventilation is of course very important for the patient. In addition, it is also important for the Belgian health care system. In many countries, mechanical ventilation and intensive care unit capacity was a vital and critical resource for COVID-19 patients. However, many additional scientific questions remain. The DAWN-plasma trial has been designed to investigate these questions in a scientifically sound way, and in alignment with other European trials, in order to enable the combination of our results.
DAWN-plasma is a collaboration between academic and non-academic centers from Flanders, Wallonia, and Brussels, the Rode Kruis Vlaanderen and Croix Rouge, and financed by the Belgian Health Care Knowledge Center (KCE). The study is coordinated by the University Hospitals Leuven (UZ Leuven), Belgium.